NCT07499128 2026-04-16
Continuous Temperature Monitoring (CTM) for Cytokine Release Syndrome (CRS), an Immune-Related Adverse Event
National Institutes of Health Clinical Center (CC)
Phase NA Not yet recruiting
Clinical Trials
152 trialsNCT07532473 2026-04-16
REMAKE
The Royal Wolverhampton Hospitals NHS Trust
Not yet recruiting
NCT07249528 2026-04-15
A Study of Voice as a Way to Monitor for Side Effects in People Receiving CAR T-Cell Therapy
Memorial Sloan Kettering Cancer Center
Phase NA Not yet recruiting
NCT07221032 2026-04-14
FT836 CAR T-cell Therapy in Combination With Daratumumab in Patients With Relapsed and/or Refractory Multiple Myeloma
Medical College of Wisconsin
Phase 1 Not yet recruiting
NCT06948084 2026-04-13
Testing the Investigational Medication Combination of Daratumumab and Teclistamab Compared to the Usual Treatment (Daratumumab, Pomalidomide, Dexamethasone or Daratumumab, Carfilzomib, Dexamethasone) for Patients With High-risk Multiple Myeloma Refractory or in First Relapse
National Cancer Institute (NCI)
Phase 2 Not yet recruiting
NCT07463807 2026-04-13
Testing the Investigational Medication Combination of Teclistamab and Pomalidomide Compared to the Usual Treatment (Carfilzomib, Pomalidomide, and Dexamethasone) for Patients With Multiple Myeloma Who Have Relapsed Shortly After Treatment
National Cancer Institute (NCI)
Phase 1/2 Not yet recruiting
NCT07518186 2026-04-13
TRIlogy-5
Janssen Research & Development, LLC
Phase 3 Not yet recruiting
NCT07524634 2026-04-13
Dose Schedule Study of BCMA Bispecific Antibody, Elranatamab, for Newly Diagnosed Immunoglobulin Light Chain (AL) Amyloidosis
Case Comprehensive Cancer Center
Phase 2 Not yet recruiting
NCT07519187 2026-04-09
CAR 70-BCMA CAR-T Cells for the Treatment of Relapsed or Refractory Plasma Cell Neoplasms
The General Hospital of Western Theater Command
Phase EARLY_PHASE1 Not yet recruiting
NCT06986434 2026-04-08
CAR19BCMA CAR-T Cells for the Treatment of R/R Plasma Cell Neoplasms and Lymphomas/Leukemias With Plasmacytic Differentiation
Affiliated Hospital to Academy of Military Medical Sciences
Phase EARLY_PHASE1 Not yet recruiting
NCT07200089 2026-04-07
Recombinant Human IL-7 (NT-I7) in Relapsed/Refractory Multiple Myeloma Following BCMA CAR-T Therapy (Cilta-cel)
Washington University School of Medicine
Phase 1 Not yet recruiting
NCT07510100 2026-04-03
FUMANBA-04
Nanjing IASO Biotechnology Co., Ltd.
Phase 1/2 Not yet recruiting
NCT06971848 2026-03-30
ETCABIO
University Hospital, Angers
Phase NA Not yet recruiting
NCT07490613 2026-03-24
A Phase I Study of SHR-3836 in Patients With Multiple Myeloma
Shanghai Hengrui Pharmaceutical Co., Ltd.
Phase 1 Not yet recruiting
NCT06987708 2026-03-23
Evaluating the Impact of a 12-month Multi-Modal Lifestyle Management Intervention on Disease Relevant Biomarkers
Hackensack Meridian Health
Phase NA Not yet recruiting
NCT07292272 2026-03-23
Halt Aging in Survivors of Blood Cancers: the HALTAging-1 Study
University of Nebraska
Phase 2 Not yet recruiting
NCT07479979 2026-03-23
Study of Selinexor With Carfilzomib, Isatuximab and Dexamethasone for Patients With Relapsed and/or Refractory Multiple Myeloma
Hoosier Cancer Research Network
Phase 1/2 Not yet recruiting
NCT07354555 2026-03-20
MMExFFPE
BIWAKO
Not yet recruiting
NCT07485647 2026-03-20
Identifying Effective and Cost-Conscious Maintenance Daratumumab Dosing
Vanderbilt-Ingram Cancer Center
Phase 2 Not yet recruiting
NCT07482761 2026-03-19
MM-t4-14-FFPE
BIWAKO
Not yet recruiting
NCT07224672 2026-03-17
ALANIS
GlaxoSmithKline
Phase 2 Not yet recruiting
NCT07477587 2026-03-17
A Study to Compare the PK Characteristics, Safety, Tolerability, and Immunogenicity of HLX15-SC With DARZALEX FASPRO® in Combination With Lenalidomide and Dexamethasone (Rd) in Transplant-ineligible Patients With Newly Diagnosed Multiple Myeloma
Shanghai Henlius Biotech
Phase 1 Not yet recruiting
NCT07393282 2026-03-16
LINKER-SMM2
Regeneron Pharmaceuticals
Phase 3 Not yet recruiting
NCT07474961 2026-03-16
BLOOD-dose
Rigshospitalet, Denmark
Phase 4 Not yet recruiting
NCT04579523 2026-03-13
²¹¹At-OKT10-B10 and Fludarabine Alone or in Combination With Cyclophosphamide and Low-Dose TBI Before Donor Stem Cell Transplant for the Treatment of Newly Diagnosed, Recurrent, or Refractory High-Risk Multiple Myeloma
Fred Hutchinson Cancer Center
Phase 1 Not yet recruiting
NCT07458659 2026-03-09
CART-BCMA
Chulalongkorn University
Phase EARLY_PHASE1 Not yet recruiting
NCT07454187 2026-03-06
To Evaluate the Safety of SG2918 in Patients With Relapsed/Refractory Multiple Myeloma
Hangzhou Sumgen Biotech Co., Ltd.
Phase 1/2 Not yet recruiting
NCT07297160 2026-03-04
CALySSEY
Baylor College of Medicine
Phase 1 Not yet recruiting
NCT07029776 2026-03-03
MMulti-Immune HR; Multi-Target Immunotherapy for High-Risk Multiple Myeloma
University of Arkansas
Phase 2 Not yet recruiting
NCT07446777 2026-03-03
FAST-M
University of Miami
Phase NA Not yet recruiting
NCT07440290 2026-02-27
DETERMINE
Cancer Research UK
Phase 2/3 Not yet recruiting
NCT07336472 2026-02-25
A Study of IBI3003 in Subjects With Relapsed or Refractory Multiple Myeloma
Fortvita Biologics (USA)Inc.
Phase 1/2 Not yet recruiting
NCT07416682 2026-02-25
CAR BCMA-70 CAR-T Cells for the Treatment of High-risk Plasma Cell Neoplasms
Affiliated Hospital to Academy of Military Medical Sciences
Phase EARLY_PHASE1 Not yet recruiting
NCT07429721 2026-02-24
A Clinical Study to Evaluate the Safety and Preliminary Efficacy of QI-019A in Patients With Relapsed/Refractory Multiple Myeloma.
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Phase EARLY_PHASE1 Not yet recruiting
NCT07426484 2026-02-23
Cosibelimab for CSCC in Patients With Kidney Transplant or Hematologic Malignancy
Dana-Farber Cancer Institute
Phase 4 Not yet recruiting
NCT07428369 2026-02-23
LINKER-MM8
Regeneron Pharmaceuticals
Phase 2/3 Not yet recruiting
NCT07421856 2026-02-19
Phase I/II Study of SENL103 for Relapsed or Refractory Multiple Myeloma: A Multicenter, Open-Label, Single-Arm Trial.
Hebei Senlang Biotechnology Inc., Ltd.
Phase 1/2 Not yet recruiting
NCT07391761 2026-02-18
A Real World Study of Elranatamab in Patients With RR Multiple Myeloma in Taiwan
Pfizer
Not yet recruiting
NCT07409454 2026-02-13
CAREMM-007
Institute of Hematology & Blood Diseases Hospital, China
Phase 2 Not yet recruiting
NCT07407010 2026-02-12
CM336-001
Institute of Hematology & Blood Diseases Hospital, China
Phase 1 Not yet recruiting
NCT07403071 2026-02-11
Validating Fish Oil's Role in Alleviating Bortezomib-Induced Neuropathy: A Multi-Method Study Integrating Big Data, Experimental, and Clinical Research
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Not yet recruiting
NCT07234721 2026-02-10
SL4903
Institute of Hematology & Blood Diseases Hospital, China
Phase EARLY_PHASE1 Not yet recruiting
NCT07399444 2026-02-10
LB2505-0001
Institute of Hematology & Blood Diseases Hospital, China
Phase EARLY_PHASE1 Not yet recruiting
NCT07400744 2026-02-10
A Study to Compare the PK , Safety, and Immunogenicity of QL2109 With Daratumumab in Male Subjects
Qilu Pharmaceutical Co., Ltd.
Phase 1 Not yet recruiting
NCT05874193 2026-02-05
COSTA
Duke University
Phase 2 Not yet recruiting
NCT07388147 2026-02-04
SAPPHIRE-MM
University Hospital Heidelberg
Phase NA Not yet recruiting
NCT07009899 2026-01-29
RECLAIM
Medical College of Wisconsin
Phase 2 Not yet recruiting
NCT07376720 2026-01-29
A Clinical Study Evaluating the Safety and Efficacy of BCMA-GPRC5D CAR-T in Patients With Relapsed/Refractory Multiple Myeloma Who Have Received Three or More Lines of Treatment
Tongji Hospital
Phase NA Not yet recruiting
NCT07376733 2026-01-29
Effects of Controlled Breathing on Cardiorespiratory Variables in Multiple Myeloma
Universidad Complutense de Madrid
Phase NA Not yet recruiting
NCT07377435 2026-01-29
DC/MM Fusion Vaccine With BCMA CAR-T in R/R MM
Beth Israel Deaconess Medical Center
Phase 1 Not yet recruiting